Aggressive Mature (CD20 ) B-cell Lymphoma
Showing 1 - 25 of >10,000
DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)
Active, not recruiting
- Diffuse Large B-Cell Lymphoma (DLBCL)
- +4 more
- EPOCH
- Rituximab
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)
Not yet recruiting
- B-cell Non-Hodgkins Lymphoma (B-NHL)
- (no location specified)
Jan 5, 2023
CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)
Recruiting
- CD20-positive B-cell Non-Hodgkin's Lymphoma
-
Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Apr 6, 2023
B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)
Recruiting
- B-cell Lymphoma
- +5 more
- Cyclophosphamide
- +3 more
-
Louisville, KentuckyNorton Cancer Institute
Jan 24, 2023
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in United States (IMPT-314)
Not yet recruiting
- Relapsed Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
-
Los Angeles, California
- +3 more
Apr 12, 2023
Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Anti-CD19 and anti-CD20 bicistronic CAR T- cells
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Apr 10, 2023
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular
Recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- +19 more
- CD47 Antagonist ALX148
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
B-cell Non-Hodgkin's Lymphoma Trial (IMM0306, Lenalidomide capsule)
Not yet recruiting
- B-cell Non-Hodgkin's Lymphoma
- IMM0306
- Lenalidomide capsule
- (no location specified)
Mar 6, 2023
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)
Not yet recruiting
- Relapsed Non-Hodgkin Lymphoma
- +6 more
- (no location specified)
Apr 12, 2023
Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Spain (ARI0003)
Not yet recruiting
- Refractory Non-Hodgkin Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- ARI0003
-
Santiago De Compostela, A Coruña, Spain
- +6 more
Oct 24, 2023
B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in China (Orelabrutinib, Recombinant humanized mAb MIL62 injection)
Active, not recruiting
- B-cell Lymphoma Recurrent
- B-cell Lymphoma Refractory
- Orelabrutinib
- Recombinant humanized monoclonal antibody MIL62 injection
-
Bengbu, Anhui, China
- +9 more
Nov 11, 2022
Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in United States (P-CD19CD20-ALLO1, Rimiducid)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- +5 more
- P-CD19CD20-ALLO1
- Rimiducid
-
La Jolla, California
- +7 more
Aug 25, 2023
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +15 more
- Anti-CD19/CD20/CD22 CAR T-Cells
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 4, 2022
B Cell Non-Hodgkin's Lymphoma Trial in Duarte (CD19/CD20-directed CAR-T cells)
Recruiting
- B Cell Non-Hodgkin's Lymphoma
- CD19/CD20-directed CAR-T cells
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 10, 2022
Resolved Hepatitis B, CD20 Positive B-cell Lymphoma Trial (Entecavir)
Not yet recruiting
- Resolved Hepatitis B
- CD20 Positive B-cell Lymphoma
- (no location specified)
Jul 10, 2022
B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma Trial in Saint Louis (Mosunetuzumab)
Recruiting
- B Cell Lymphoma
- +5 more
-
Saint Louis, MissouriWashington University School of Medicine
Jan 3, 2023
Non-Hodgkin's Lymphoma Trial in Philadelphia (drug, procedure, genetic)
Completed
- Non-Hodgkin's Lymphoma
- Bendamustine
- +6 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Sep 14, 2022
Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate
Recruiting
- Aggressive Non-Hodgkin Lymphoma
- +8 more
- Polatuzumab Vedotin
- +6 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 26, 2023
Cardiovascular Events Among Adults Relapsed or Refractory
Recruiting
- Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
- +9 more
- Electronic Health Record Review
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive
Active, not recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- fractionated first dose rituximab
-
Geneva, SwitzerlandUniversity Hospital Geneva
Apr 21, 2023
Advanced Malignancies Trial in Beijing (1A46 Drug Substance)
Not yet recruiting
- Advanced Malignancies
- 1A46 Drug Substance
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Aug 4, 2023
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
- CD19/CD22-bispecific CAR-T cells
-
Beijing, Beijing, ChinaLiang Wang
Oct 7, 2023
Mature B-Cell Non-Hodgkin Lymphoma Trial (Obinutuzumab, Glofitamab, Rituximab)
Not yet recruiting
- Mature B-Cell Non-Hodgkin Lymphoma
- Obinutuzumab
- +6 more
- (no location specified)
Sep 6, 2022
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston
Not yet recruiting
- Refractory Aggressive B-cell Lymphomas
- +12 more
- ACALABRUTINIB
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 13, 2022
Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma Trial in China (Relmacabtagene
Not yet recruiting
- Lymphoma, Large B-Cell, Diffuse
- +3 more
- Relmacabtagene Autoleucel
- +2 more
-
Guangzhou, Guangdong, China
- +12 more
Oct 24, 2023